Trials / Completed
CompletedNCT04512287
PRP for Treatment of Peyronie's Disease
A Randomized, Double-Blind, Placebo Controlled, Crossover Trial on Safety and Efficacy of Autologous Platelet-Rich Plasma for Treatment of Peyronie's Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 65 (actual)
- Sponsor
- University of Miami · Academic / Other
- Sex
- Male
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to learn about the effects of Platelet-Rich Plasma (PRP) injection in men with Peyronie's Disease (PyD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Autologous Platelet Rich Plasma | 2 sessions of Autologous PRP will be administered 15 days apart. Each injection will be 0.5 mL of PRP injected into the Peyronie's disease penile plaque. |
| OTHER | Saline Solution | 2 sessions of saline injection will be administered 15 days apart. Each injection will be 0.5 mL of normal saline injected into the Peyronie's disease penile plaque. |
Timeline
- Start date
- 2021-03-29
- Primary completion
- 2025-08-11
- Completion
- 2025-08-11
- First posted
- 2020-08-13
- Last updated
- 2025-08-14
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04512287. Inclusion in this directory is not an endorsement.